Martí Jiménez‐Mausbach

Semaglutide attenuates a proteomics‐based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial

Martí Jiménez‐Mausbach, Betty Marije Tijms, Clare Paterson, Jan C. Refsgaard

Abstract INTRODUCTION Plasma proteomics detect multi‐pathway biological changes preceding dementia onset. The Dementia SomaSignal Test (dSST) is a validated 25‐protein score predicting 5‐ and 20‐year all‐cause dementia risk. Preclinical and clinical data suggest glucagon‐like peptide‐1 receptor agonists may have neuroprotective effects. METHODS …

dk, nl, us (code pays fourni par la source)

Medical comorbidities of patients receiving amyloid‐targeting treatments in a memory clinic

William J. B. Powell, Suzanne Elizabeth Schindler, Martí Jiménez‐Mausbach, Inez Y. Oh et autres

INTRODUCTION: Trials of amyloid-targeting treatments (ATTs) for early symptomatic Alzheimer's disease (AD) enrolled selected patients with minimal medical comorbidities. We investigated whether real-world memory clinic patients who received ATTs also had fewer comorbidities than the broader clinic population. METHODS: We extracted data …

us, dk (code pays fourni par la source)

Early Alzheimer’s Disease Diagnosis and Blood Biomarkers: Primary Care Physician Attitudes, Perceptions, and Barriers in the USA (P4-12.009)

Susan Alford, Sheena K. Aurora, Justine Coppinger, Martí Jiménez‐Mausbach et autres

To uncover primary care physicians’ (PCPs’) attitudes on, perceptions of and barriers to Alzheimer’s disease (AD) diagnosis and incorporating blood biomarkers (BBMs) into the diagnostic workflow.

gb, us, dk, pt (code pays fourni par la source)

Defining the natural history of Alzheimer’s disease by longitudinal cerebrospinal fluid proteomics.

Betty Marije Tijms, Diederick de Leeuw, Calvin Trieu, Martí Jiménez‐Mausbach et autres

nl, dk, no (code pays fourni par la source)

Early Alzheimer's diagnosis: U.S. primary care physicians and use of blood biomarkers

J.B. Burns, Susan Alford, Justine Coppinger, Martí Jiménez‐Mausbach et autres

INTRODUCTION: We aimed to explore primary care physicians' (PCP) attitudes, perceptions, and barriers toward Alzheimer's disease (AD) diagnosis and incorporating blood biomarker (BBM) tests into the diagnostic workflow. METHODS: Remote 60-min interviews with 20 PCPs were conducted (May 2023). Participants included generalists …

us, dk, pt (code pays fourni par la source)

Early Alzheimer's disease diagnosis and blood biomarkers: primary care physician attitudes, perceptions and barriers in the USA

Susan Alford, Sheena K. Aurora, Justine Coppinger, Martí Jiménez‐Mausbach et autres

BACKGROUND: Early and accurate diagnosis of Alzheimer's disease (AD) is critical for ensuring access to targeted lifestyle recommendations and disease modifying therapies (DMT), which can slow disease progression. Historically, diagnosis has been slow, complex, costly, inaccurate, and inconsistent, with individuals often diagnosed …

us, dk, pt (code pays fourni par la source)

General practitioners’ perspectives on blood biomarkers for Alzheimer's disease

Thomas Claessen, Fleur C W Visser, Barbara C. Van Munster, Wiesje M. van der Flier et autres

BACKGROUND: Alzheimer's disease (AD) blood biomarkers could improve the diagnostic process for patients with cognitive complaints presenting to primary care. We investigated general practitioners' (GPs') perspectives on facilitating and hindering factors associated with the use and implementation of AD blood biomarkers. METHOD: …

nl, dk, us (code pays fourni par la source)

Exploring barriers and facilitators for the implementation of Alzheimer’s disease blood‐based biomarkers in primary care: The CANTATE‐Perspectives study

Thomas Claessen, Fleur C W Visser, Barbara C. Van Munster, Wiesje M. van der Flier et autres

Abstract Background Adequately diagnosing Alzheimer’s disease (AD) in primary care can be challenging. Early symptoms often go unrecognized and other (neurodegenerative) diseases may be misdiagnosed as AD. AD blood‐based biomarkers could improve the diagnostic process for cognitive complaints in primary care. To …

nl, dk, se (code pays fourni par la source)